PDF(Pubmed)
Abstract：
We examined the effect of a dietary seaweed extract-sulfated xylorhamnoglucuronan (SXRG84)-on individuals with inflammatory skin conditions. A subgroup analysis of a larger trial was undertaken, where 44 participants with skin conditions were enrolled in a double-blind placebo-controlled crossover design. Subjects ingested either SXRG84 extract (2 g/day) for six weeks and placebo for six weeks, or vice versa. At baseline, six- and twelve-weeks inflammatory markers and the gut microbiota were assessed, as well as skin assessments using the dermatology quality of life index (DQLI), psoriasis area severity index (PASI) and visual analogue scales (VAS). There were significant differences at weeks six and twelve for pro-inflammatory cytokines IFN-γ (p = 0.041), IL-1β (p = 0.030), TNF-α (p = 0.008) and the anti-inflammatory cytokine IL-10 (p = 0.026), determined by ANCOVA. These cytokines were all significantly higher at six weeks post placebo compared to twelve weeks post placebo followed by SXRG84 treatment. A total of 23% of participants reported skin improvements, as measured by VAS (mean difference 3.1, p = 0.0005) and the DQLI score (mean difference -2.0, p = 0.049), compared to the \'non-responders\'. Thus, the ingestion of SXRG84 for 6 weeks reduced inflammatory cytokines, and a subset of participants saw improvements.
摘要：
我们研究了饮食海藻提取物硫酸化的木沙鼠葡糖醛酸（SXRG84）对患有炎性皮肤病的个体的影响。对一项更大的试验进行了亚组分析，其中44名患有皮肤疾病的参与者被纳入双盲安慰剂对照交叉设计。受试者摄入SXRG84提取物（2克/天）六周，安慰剂六周，反之亦然。在基线,评估了6周和12周的炎症标志物和肠道微生物群，以及使用皮肤病学生活质量指数（DQLI）进行的皮肤评估，银屑病面积严重度指数(PASI)和视觉模拟量表(VAS)。促炎细胞因子IFN-γ在第6周和第12周存在显着差异（p=0.041），IL-1β（p=0.030），TNF-α（p=0.008）和抗炎细胞因子IL-10（p=0.026），由ANCOVA确定。这些细胞因子均在安慰剂后6周显著高于随后SXRG84治疗的安慰剂后12周。共有23%的参与者报告皮肤改善，通过VAS（平均差3.1，p=0.0005）和DQLI评分（平均差-2.0，p=0.049）衡量，与“非响应者”相比。因此，摄入SXRG84持续6周可减少炎症细胞因子，一部分参与者看到了改进。
